Hot Deals:
5 star business 494.00 (-0.20 %) a v thomas 11,770.00 (-0.25 %) amol minechem 620.00 (1.64 %) anand i-power 20.00 anglo french 370.00 (-2.37 %) aricent 575.00 (0.88 %) arkfin investments 50.00 arohan 181.00 (0.56 %) assam carbon 227.00 (-1.30 %) associated pigments 42.00 (-4.55 %) atlas copco 7,000.00 (27.27 %) auckland 130.00 (-3.70 %) axles 160.00 (5.96 %) b9 bira 772.00 (0.26 %) balmer lawrie 300.00 bharat hotels 162.00 (1.25 %) bikaji foods 390.00 (1.04 %) bima mandi 700.00 boat 840.00 (5.00 %) c & s electric 470.00 (-4.08 %) capgemini 12,250.00 (2.08 %) care health 135.00 (0.75 %) carrier aircon 260.00 (1.96 %) cial 180.00 (-1.64 %) csfbl 265.00 (-3.64 %) csk 150.00 (-3.23 %) dalmia refract 81.00 (-4.71 %) dsp merrill lynch 1,000.00 east india pharma 44.00 (2.33 %) eaton fluid 380.00 (1.33 %) electronica plastic 4,100.00 (-4.65 %) elgi ultra 400.00 elofic 1,909.00 (0.47 %) epiroc 1,224.00 (-2.08 %) esl steel 35.00 (2.94 %) fincare business 43.00 fincare sfbl 74.00 (1.37 %) fino paytech 160.00 (3.23 %) frick india 3,806.00 (0.16 %) gkn drive 1,240.00 (-0.80 %) go digit gil 350.00 godavari bio 71.00 (1.43 %) hdbfsl 600.00 (-2.44 %) hdfc ergo 363.80 hdfc securities 11,600.00 (-0.85 %) hella india 330.00 (1.54 %) hero fincorp 690.00 (-3.36 %) hicks 2,100.00 (-2.55 %) hira ferro 120.00 (-0.83 %) honeywell electrical 3,555.00 (-1.25 %) icex 5.01 (0.20 %) incred financial 100.00 india carbon 1,010.00 (1.00 %) india exposition 146.00 (0.69 %) indian potash 1,405.00 (0.36 %) indofil 710.00 (-1.39 %) infinite computer 700.00 inkel 12.95 (-0.38 %) ixigo 97.00 (-2.02 %) jana sfbl 75.00 kial 107.00 (-2.73 %) kurlon enterprise 640.00 (-3.03 %) kurlon limited 426.00 (-3.18 %) lava 127.00 (0.79 %) manipal hfsl 72.50 (0.69 %) manjushree tech 1,001.00 (-0.89 %) martin & harris 1,495.00 (-0.33 %) merino 2,750.00 (1.85 %) minosha 280.00 (-3.45 %) mitsubishi heavy 355.00 (1.43 %) mkcl 415.00 (1.22 %) mobikwik 450.00 (-4.26 %) mohan meakin 1,212.00 (1.00 %) mohfl 11.90 (-1.65 %) msei 1.00 (-4.76 %) msil 56.00 (3.70 %) nayara energy 151.00 (0.67 %) nayara energy ncd 250.00 ncdex 275.00 ncl buildtek 195.00 (2.63 %) ncl holdings 47.50 (1.06 %) nse 3,100.00 (-1.59 %) orbis financial 68.00 (1.49 %) oswal minerals 65.00 (1.56 %) otis 3,800.00 (-2.56 %) oyo rooms 91.00 (1.11 %) panasonic appliances 293.00 (-4.25 %) panasonic avc 29.10 (0.34 %) paymate india 600.00 (-3.38 %) pharma easy 35.00 (-2.78 %) philips domestic 605.00 (0.83 %) philips india 1,100.00 (1.85 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 530.00 (0.57 %) rasoi 32,000.00 (3.23 %) reliance gic 340.00 resins plastics 414.00 (1.97 %) ring plus 370.00 (1.37 %) rrl 2,950.00 (1.72 %) sab miller 303.00 (1.00 %) satya micro 201.00 (0.50 %) scottish assam 520.00 (-7.96 %) shriram life 251.00 (0.40 %) sigachi lab 40.10 (0.25 %) signify 1,100.00 (4.46 %) simpson & company 3,500,000.00 smile microfin 52.00 (-1.89 %) sportskeeda 3,303.00 sterlite power 1,000.00 (-1.96 %) studds 950.00 (-5.00 %) svsml 510.00 (-2.30 %) t stanes 675.00 tata capital 55.00 (7.84 %) tata tech 5,555.00 (1.00 %) teesta agro 70.00 (-22.22 %) tmbl 515.00 (3.00 %) trl krosaki 1,224.00 (-2.16 %) utkarsh core 127.00 (-2.31 %) vikram solar 55.50 (-0.89 %) xerox 243.00 (1.25 %)
×

arch pharma labs Limited

55.00
+ 1.85 %
Scrip Name
Arch Pharma
ISIN No.
INE182F01017
PAN No.
AACCM0306Q
Face Value
10
No. of Outstanding Shares
151,923,076
Market Capitalization
835.58 Crore

ARCH PHARMALABS LIMITED UNLISTED SHARE


ABOUT ARCH PHARMA LABS LIMITED


ARCH PHARMA LABS LIMITED is a pharmaceutical company aligned across two business verticals viz. Products and Services. The Products business of the company comprises the manufacture and sale of Active Pharmaceutical Ingredients (“API”) and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. In services business of the company includes Contract Research and Manufacturing Services (“CRAMS”). Currently, the company owns and manages 9 multipurpose manufacturing facilities.


The Company has a diversified portfolio and offers more than 120 products ( over 65 APIs and over 55 Intermediates) across various therapeutic segments, such as lipid-lowering agents, oncology, anti-platelet agents, anti-asthmatic,anti-retroviral, anti-anginal, calcium channel blockers, anti-hypertensive,anti-histamine, anti-diabetic, anti-protozoal, anti-fungal, anti-emetic, proton pump inhibitors, expectorant, anti-depressant, decongestant, anti-convulsant, psychostimulant, hypnotic, anti-parkinsonian, anti-gout, analgesic, and others.


The Company provides contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale-up to technology transfer, clinical-trial manufacturing, and commercial manufacture.


Arch Pharmalabs Limited has technology tie-ups with Codexis (USA), Orochem Technologies (USA), and DSM (Netherlands). The use of these technologies helps the company to implement various green chemistry initiatives which are not only environmentally friendly but also reduce production costs.



INCORPORATION DETAILS


CIN

U24231MH1993PLC150891

Registration Date

02 April 1993

Category/Sub-category of the Company

Company Limited by Shares

Address of the Registered office and contact details

3rd Floor, Titanic Building, Chandivali Farm Road,

Nr. HDFC Bank, Andheri (East), Mumbai - 400072.

Tel. : +91-22-4287 1210

Name, Address and Contact Details of

Registrar and Transfer Agent, if any

Link Intime India Private Limited

C-101, 247 Park, L.B.S Marg,

Vikhroli (West), Mumbai - 400083,

Tel: 022-25946970

 

PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Name and Description of main products/services

NIC Code of the product/service

% to total turnover of the Company

Pharmaceutical products

21002 & 21005

100%

 

BOARD OF DIRECTORS

Mr. Ajit Kamath (Chairman & Managing Director)

Mr. Rajendra Kaimal (Executive Director & CFO)

Mr. Ashish Ujagare (Executive Director)

Dr. Sunil Pitroda (Independent Director)


PARTICULARS OF SUBSIDIARY AND ASSOCIATE COMPANIES

Name of the Company

Subsidiary/Associate

% of shares held

Arch Life SciencesLimited

Subsidiary

58.46%

Arch FinechemicalsLimited

Subsidiary

88.95%

Arch Pharmalabs FZLLC

Subsidiary

100.00%

Kobo Biotech Limited

Associate

44.95%


SHAREHOLDING PATTERN

(As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Arch Impex Private Limited

5,54,05,664

36.47%

2

Arch PharmachemLimited

2,11,81,000

13.94%

3

ArchAgroIndustriesPrivate Limited

61,54,754

4.05%

4

AMR InvestmentsPrivate Limited

19,76,681

1.30%

5

Arch Herbals Private limited

62,42,076

4.11%

6

Public Shareholding

6,09,62,901

40.12%

 

Total

15,19,23,076

100.00%


INDUSTRY OUTLOOK

 

The Global pharmaceutical industry is valued at around US$ 1250 billion. The US market alone accounts for 48% of the market. India and China each stand at US$ 53 billion and US$ 190 billion respectively. India is the largest provider of generic drugs and is fulfilling around 20% of the global demand.


In the Active Pharmaceutical Ingredients (API) Industry, if we see the units approved by USFDA, US leads with 28% approval rating, Europe with 26%, and India & China with 18% and 13% respectively. It is the best time for India to focus on building and improving its API manufacturing and export capabilities. According to Statistics, the Indian API market is projected to grow at a CAGR of 8.57% from 2020 to 2026. The Government of India has announced Rs. 6,940 Crore Production Linked Incentive (PLI) scheme to boost drug manufacturing in India. The scheme is mainly aimed at reducing imports through the promotion of domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and Drug Intermediates.


Pharmaceutical Companies are continuously increasing outsourcing research activities to academic and private contract research organizations (CROs) to become and stay competitive in the market. After the COVID 19 pandemic, the pharmaceutical industry has gotten a new direction and is currently experiencing dynamic changes. That is why to reduce their R&D expenses, the companies to a significant extent are now relying on outsourcing service providers. Based on this, the opportunities available to India are Custom Chemical Synthesis or CCS, clinical trials, and contract manufacturing or CRAMS. However, the most scalable opportunity for Indian companies lies in contract manufacturing or CRAMS. This is because CRAMS supplies are linked to the success of a product post commercialization and can provide relatively stable revenues.


PROFIT & LOSS STATEMENT OF ARCH PHARMA LABS LIMITED(In Rs. Crores)

 

Particulars

FY 2020

FY 2019

FY 2018

Revenue from Operations

632.29

476.58

247.19

EBITDA

38.43

14.05

-263.02

Finance Cost

204.67

162.84

82.52

Depreciation

30.30

32.54

39.10

Other Income

19.22

38.20

0.25

Profit Before Tax and Exceptional items

-177.32

-143.12

-384.39

Exceptional items

17.13

12.14

323.25

Total Tax

-0.69

0.34

0.00

Profit After Tax (PAT)

-159.50

-131.31

-61.14

EPS

-10.5

-8.64

-8.92

 

BALANCE SHEET OF ARCH PHARMA LABS LIMITED (In Rs. Crores)


PARTICULARS

2020

2019

ASSETS



NON-CURRENT ASSETS



Tangible assets

998.36

1052.33

Intangible assets

5.18

9.17

Goodwill ( On Consolidation)

9.71

9.71

Financial assets

207.11

207.33

TOTAL NON-CURRENT ASSETS

1,220.36

1,278.55

CURRENT ASSETS



Inventories

832.58

729.71

Trade receivables

439.39

589.61

Cash and Cash Equivalents

2.77

4.19

Short-term loans and advances

614.29

628.74

TOTAL CURRENT ASSETS

1,889.02

1,952.25

TOTAL ASSETS

3,109.38

3,230.80

EQUITY AND LIABILITIES



Share Capital

151.92

151.92

Share Application Money

17.51

17.51

Surplus

-1,776.35

-1,582.75

Minority Interest

3.39

3.39

TOTAL EQUITY

-1,603.52

-1,409.92

NON-CURRENT LIABILITIES



Long-term borrowings

3,070.84

3,451.14

TOTAL NON-CURRENT LIABILITIES

3,070.84

3,451.14

CURRENT LIABILITIES



Short-term borrowings

113.12

113.22

Trade payables

475.48

550.94

Other current liabilities

1,048.25

520.22

Short-term provisions

5.21

5.21

TOTAL CURRENT LIABILITIES

1,642.06

1,189.58

TOTAL LIABILITIES

4,712.90

4,640.72

TOTAL EQUITY AND LIABILITIES

3,109.38

3,230.80

 

DIVIDEND HISTORY

Particulars

2020

2019

2018

Dividend (final + interim) (In Rs.)

Nil

Nil

Nil

 

PERFORMANCE OF THE COMPANY

The revenue from operations of the company increased by 32.67% from Rs. 486.58 Crore in FY 2019 to Rs. 632.29 Crore in FY 2020. The increase in revenue can mainly be attributed to the increase in operational activities at the manufacturing sites and is expected to continue in the coming few years.


EBITDA of the company has increased by 173% from Rs. 14.05 Crore in FY 2019 to Rs. 38.43 Crore in FY 2020. EBITDA margins have improved from 2.95% in FY 2019 to 6.08% in FY 2020.


The finance cost of the company increased by 25.68% from Rs. 162.84 Crore in FY 2019 to Rs. 204.67 Crore in FY 2020.


The company has incurred a loss of Rs. 131.31 Crore in FY 2019, which increased to a loss of Rs. 159.50 Crore in FY 2020. These losses are mainly because of the increasing financial cost of the company.


The current Ratio of the company as of 31st March 2020 was 1.15.


The Company has not given any dividend for the past three years.

Powered by Froala Editor

Wealth Wisdom - WWIPL
Support Megha Support Neha Support Pallavi